mRNA vaccines found to generate neutralizing antibodies against SARS-CoV-2 Omicron variant

In a recent study posted to the medRxiv* preprint server, researchers assessed the immunogenicity of messenger-ribonucleic acid (mRNA) vaccines to generate cross-reactive neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) in convalescent coronavirus disease 2019 (COVID-19) patients. Study: Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two […]
Continue reading »